Abstract
Background: The high molecular weight and increasing lipophilicity of drug face many problems starting from the drug development to formulation and conduction of pharmacological, toxicological and pharmacokinetic studies to its biological application. To overcome this problem, nano-sized formulations are in trend recently. The use of Solid lipid nanoparticles (SLNs) offers new insight into the formulation of the poor soluble and low bioavailable drug.
Objective: The study aimed to investigate the literature concerning the development of SLNs for oral drug delivery of poorly soluble drugs, with a view survey the various methods of manufacturing and evaluation of formulation of SLNs and future prospects of SLNs and application of SLNs in oral delivery systems.
Conclusion: Oral drug delivery is looking ahead progressively into newer directions due to the realization of various poor performance limiting factors such as reduced drug solubility or absorption, rapid metabolism, high actuation in plasma level of drug and variability caused due to food effect. These play a vital role in disappointing in vivo results, which leads in the failure of the conventional delivery system. Since the last decade, oral drug delivery has taken a new dimension with the increasing application of SLNs as a carrier for the delivery of poorly water-soluble or lipophilic drugs. The site-specific and sustained release effect of the drug is better achieved by using SLNs. This review highlights the various pros and cons, manufacturing techniques, characterization, and future prospects of SLNs in oral drug delivery systems.
Keywords: Oral drug delivery, novel drug delivery system (NDDS), solid lipid nanoparticles (SLNs), bioavailability, nano-sized formulations, drug solubility.
Graphical Abstract
[http://dx.doi.org/10.2174/187221109788452267] [PMID: 19519576]
[http://dx.doi.org/10.7897/2230-8407.04312]
[http://dx.doi.org/10.1016/S1359-0286(02)00117-1]
[http://dx.doi.org/10.2174/2468187306666160603120318]
[http://dx.doi.org/10.1016/S1461-5347(00)00255-8] [PMID: 10785658]
[http://dx.doi.org/10.2174/156720105774370267] [PMID: 16305433]
[http://dx.doi.org/10.1016/0378-5173(86)90134-1]
[http://dx.doi.org/10.1016/0378-5173(93)90015-8]
[http://dx.doi.org/10.1208/s12249-017-0901-3] [PMID: 28983849]
[http://dx.doi.org/10.7324/JAPS.2016.601017]
[http://dx.doi.org/10.3329/icpj.v1i11.12065]
[http://dx.doi.org/10.1517/17425240802712590] [PMID: 19239388]
[PMID: 24403661]
[http://dx.doi.org/10.1208/s12249-019-1337-8.]]
[http://dx.doi.org/10.4314/tjpr.v14i2.3]
[http://dx.doi.org/10.9790/3013-26103444]
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[http://dx.doi.org/10.1023/A:1016212804288] [PMID: 7617530]
[http://dx.doi.org/10.1016/j.addr.2007.10.012] [PMID: 18155800]
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[http://dx.doi.org/10.15171/apb.2015.022] [PMID: 26236652]
[http://dx.doi.org/10.1088/1742-6596/187/1/012047]
[http://dx.doi.org/10.1016/j.addr.2007.04.010] [PMID: 17582648]
[http://dx.doi.org/10.1016/S0378-5173(02)00149-7] [PMID: 12176227]
[http://dx.doi.org/10.1016/j.scp.2017.07.002]
[http://dx.doi.org/10.1016/j.colsurfb.2015.12.033] [PMID: 26764112]
[http://dx.doi.org/10.1016/j.ijpharm.2009.01.014] [PMID: 19429280]
[http://dx.doi.org/10.1016/S0939-6411(02)00130-3] [PMID: 12551713]
[http://dx.doi.org/10.1186/1476-511X-11-72] [PMID: 22695222]
[http://dx.doi.org/10.1016/j.jconrel.2005.07.023] [PMID: 16169111]
[http://dx.doi.org/10.1016/j.tube.2005.08.009] [PMID: 16256437]
[http://dx.doi.org/10.1016/j.jconrel.2006.05.010] [PMID: 16828192]
[http://dx.doi.org/10.1016/j.ejpb.2005.03.006] [PMID: 16011893]
[http://dx.doi.org/10.1016/j.msec.2013.01.037] [PMID: 23498204]
[http://dx.doi.org/10.1080/03639040802130061] [PMID: 18665980]
[http://dx.doi.org/10.1016/j.jconrel.2008.03.021] [PMID: 18499294]
[http://dx.doi.org/10.1016/j.jconrel.2008.10.002] [PMID: 18951932]
[http://dx.doi.org/10.1016/S0939-6411(01)00167-9] [PMID: 11522487]
[http://dx.doi.org/10.1016/S0939-6411(00)00087-4] [PMID: 10840199]
[http://dx.doi.org/10.1023/A:1018888927852] [PMID: 10350020]
[http://dx.doi.org/10.1016/S0378-5173(96)04731-X]
[http://dx.doi.org/10.1111/j.2042-7158.1990.tb07033.x] [PMID: 1983142]
[http://dx.doi.org/10.1155/2014/854018]
[http://dx.doi.org/10.1016/S0378-5173(02)00035-2] [PMID: 11955810]
[http://dx.doi.org/10.1016/S0927-7765(99)00157-5] [PMID: 10915953]
[http://dx.doi.org/10.21276/apjhs.2015.2.2.14]
[PMID: 18019829]
[http://dx.doi.org/10.4155/tde.10.7] [PMID: 22816120]
[http://dx.doi.org/10.4103/0975-1483.83765] [PMID: 21897661]
[http://dx.doi.org/10.1155/2013/584549]
[http://dx.doi.org/10.3109/03639045.2015.1024685] [PMID: 25830370]
[http://dx.doi.org/10.3109/10717544.2014.914986] [PMID: 24865287]
[http://dx.doi.org/10.1080/03639045.2016.1275666] [PMID: 28005442]
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.040] [PMID: 29107614]
[http://dx.doi.org/10.2174/2211738507666190802140607] [PMID: 31376827]
[http://dx.doi.org/10.1080/03639045.2019.1593434] [PMID: 30880488]
[http://dx.doi.org/10.1016/j.ijpharm.2004.12.030] [PMID: 15885464]
[http://dx.doi.org/10.1016/j.jfda.2017.02.001] [PMID: 28911663]